VALDOXAN AFTER ACUTE CORONARY SYNDROME CONCURRENT WITH DEPRESSION
- Authors: Kotov A.1
-
Affiliations:
- A.A. Ostroumov City Clinical Hospital Thirty-Three
- Issue: Vol 25, No 4 (2014)
- Pages: 32-35
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115905
- ID: 115905
Cite item
Open Access
Access granted
Abstract
The use of Valdoxan after acute coronary syndrome concurrent with depression leads to considerable clinical improvement.
Keywords
Full Text
About the authors
A. Kotov
A.A. Ostroumov City Clinical Hospital Thirty-Three
Email: alexkot1966@rambler.ru
References
- Всемирная организация здравоохранения. Доклад о состоянии здравоохранения в мире. Нью-Йорк, 2001.
- Иванов С.В. Вальдоксан (агомелатин) при терапии умеренных и тяжелых депрессий непсихотического уровня в амбулаторной и госпитальной практике (результаты Российского мультицентрового исследования «ХРОНОС») // Психиатрия и психофармакотерапия. - 2009; 11 (6): 14-7.
- Краснов В.Н. Депрессии и сердечно-сосудистые заболевания // Практ. врач. - 2002; 2: 31-2.
- Ariyo A., Haan M., Tangen C. et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group // Circulation. - 2000; 102 (15): 1976-80.
- de Bodinat C., Guardiola-Lemaitre B., Mocaër E. et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development // Nature Reviews Drug Discovery. - 2010; 9: 628-42.
- Engel B., Talan M. Diurnal variation in central venous pressure // Acta. Physiol. Scand. - 1991; 141: 273-8.
- Kennedy S. Agomelatine. Efficacy at Each Phase of Antidepressant Treatment // CNS Drugs. - 2009; 23 (2): 41-7.
- Kennedy S., Rizvi S. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. Review Article Department of Psychiatry, University Health Network, Toronto, Ontario, Canada. 2010 Jun;24(6):479-99. doi: 10.2165/11534420-000000000-00000. PMID: 20192279 [PubMed - indexed for MEDLINE]
- Lee Y., Chen H., Hsiao G. et al. Protective effects of melatonin on myocardial ischemia/reperfusion injury in vivo // J. Pineal Res. - 2002; 33: 72-80.
- Montgomery S., Kennedy S., Burrows G. et al. Absence of discontinuation symptoms with agomelatine and occurence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study // Int. Clin. Psychopharmacol. - 2004; 19 (5): 271-80.
- Portaluppi F., Montanari L., Bagni B. et al. Circadian rhythms of atrial natriuretic peptide, blood pressure and heart rate in normal subjects // Cardiology. -1989; 76: 428-32
- Qurea-Salva M., Lemoine P., Guilleminault C. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. 2010 Apr; 25(3):222-9. doi: 10.1002/hup.1112. Sleep Unit, Raymond Poincaré Hospital, Garches, APHP, France. PMID: 20373473 [PubMed - indexed for MEDLINE]
- Rudisch B. Nemeroff C. Epidemiology of comorbid coronary artery disease and depression // Biol. Psychiatry. - 2003; 54 (3): 227-40
- Stahl S., Fava M., Ttivedi M. et al. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. 2010 May;71(5):616-26. doi: 10.4088/JCP.09m05471blu. Epub 2010 Mar 23. 1930 Palomar Point Way, Ste 103, Carlsbad, CA 92008, USA. PMID: 20361916[PubMed - indexed for MEDLINE]
- Vacas M., Del Zar M., Martinuzzo M., et al. Inhibition of human platelet aggregation and thromboxane B2 production by melatonin. Correlation with plasma melatonin levels // J. Pineal Res. - 1991; 11: 135-9
- Viswanathan M., Laitinen J., Saavedra J. Expression of melatonin receptors in arteries involved in thermoregulation // Proc. Natl. Acad. Sci. U.S.A. - 1990; 87: 6200-3
- Медведев В.Э., Епифанов А.В. Инновационный метод терапии депрессий у пациентов с ишемической болезнью сердца // Обозрение психиатрии и мед. психологии им. В.М. Бехтерева. - 2010; 3: 31-6
- Котов А.М., Стоцкий А.Д., Колесников А.Б. Антидепрессанты в кардиологии // Клин. медицина. - 2012; 10: 11-6
Supplementary files
